Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2) (UST1D2)

• ClinicalTrials.gov Identifier: NCT03941132
• Recruitment Status: Recruiting
• First Posted: May 7, 2019
• Last Update Posted: January 29, 2021
• Sponsor: University of British Columbia
• Collaborators: Juvenile Diabetes Research Foundation; Janssen, LP
• Information provided by (Responsible Party): Jan Dutz, University of British Columbia

Study Description

Brief Summary:

In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a lifelong need for daily insulin injections. Even with insulin injections, blood glucose (sugar) control is imperfect and leads to many health complications and a shortened life span. Our pilot study (NCT02117765) has informed us that Ustekinumab is safe in the treatment of participants with recent-onset T1D. Ustekinumab is currently licensed for use in psoriasis where it has proven to be both highly effective and safe. The investigators hope that if the drug can block immune cells soon after the development of diabetes, any remaining insulin-producing cells may be protected, and regenerate, thus producing more insulin so that individuals may be insulin free, or require less insulin. This trial will assess the efficacy of Ustekinumab in decreasing C-peptide decline (proxy for endogenous insulin production) in participants with recent onset T1D.

Condition or disease	Intervention/treatment	Phase
Type 1 Diabetes Mellitus	Drug: Ustekinumab; Drug: Placebo	Phase 2; Phase 3

Detailed Description:

This is a randomized, placebo-controlled, double-blinded, multi-centre phase II/II study to assess efficacy and safety of Ustekinumab (STELARA®) in patients with T1D. The investigators will perform a phase II/III clinical trial with a total of 66 adult (18-25 years old) subjects with recent-onset T1D. There will be two study cohorts, with a drug:placebo ratio of 2:1. Patients receiving the study drug will receive a loading dose of 6mg/kg Ustekinumab IV given at week 0. Thereafter, 90mg Ustekinumab subcutaneously given at weeks 8, 16, 24, 32, 40, 48 (total of 7 doses). Patients randomized to receive placebo will receive respective amounts of a saline-placebo. An additional non-dosing visit at the midpoint (week 28) is required to measure 2-hour C-peptide during a MMTT. Patients will be followed for 78 weeks following the first dose. There will be a total of 10 study visits over 78 weeks, three of which are non-dosing and follow-up visits. Recruitment and screening for the study will be completed within the first 24 months. The follow up period is 1 and 1.5 years from the first dose.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 66 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: There will be a total of 60 patients enrolled in the study. The study participants will be enrolled at 2 centers (Vancouver and Toronto), and will be referred by adult or pediatric endocrinologists. This sample size estimation is based on results from week 52 C-peptide AUC values observed in the pilot UST1D study and the expected 1-year C-peptide decline in adult-onset T1D patients. Using a 2:1 Ustekinumab vs. placebo randomized assignment, a sample size of 60 yields 85% power to detect improvement in C-peptide function (alpha = 0.05) in the Ustekinumab group for an unstratified analysis at 12 months. Sixty-six participants (44 active: 22 placebo) will be recruited to allow for an approximate 10% loss to follow-up.
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
• Actual Study Start Date: January 4, 2021
• Estimated Primary Completion Date: January 2024
• Estimated Study Completion Date: August 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: Ustekinumab; Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously. Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously. Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered. Total of 11 visits	Drug: Ustekinumab; Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously. Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously.; Other Name: Stelara
Placebo Comparator: Saline Solution - Placebo; Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals. Week 0: Loading dose of 6mg/kg saline intravenously. Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously. Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered. Total of 11 visits	Drug: Placebo; Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals. Week 0: Loading dose of 6mg/kg saline intravenously. Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously.; Other Name: Saline solution

Outcome Measures

Primary Outcome Measures :

1. Baseline change in 2-hour mixed meal-stimulated C-peptide AUC at week 52. [ Time Frame: Week 52 ]
2. Rate, frequency and severity of all adverse events including; hypoglycemic episodes; injection reactions; hypersensitivity reactions; evidence of infection and posterior leukoencephalopathy syndrome. [ Time Frame: Week 52 ]

Secondary Outcome Measures :

1. 2-hour MMTT-stimulated C-peptide AUC at weeks 28 and 78) [ Time Frame: Weeks 28 and 78 ]
2. HbA1C and insulin use in units per kg body weight per day at weeks 0, 8, 16, 24, 28, 32, 40, 48, 52, 78. [ Time Frame: 78 Weeks ]
3. Immune phenotyping via flow cytometry of all IL-12, IL-23, IL-17, IFN-γ secreting immune subsets at weeks 0, 32, 52, 78). [ Time Frame: 78 Weeks ]
4. Basic immune phenotyping of WBC subsets [ Time Frame: 78 Weeks ]
5. HLA- A, B, C, DR, DP, DQ typing at weeks 0, 8 ,16, 32, 52, 78) [ Time Frame: 78 Weeks ]
6. Fluorospot (ELISpot) analysis for IL-17 and IFN-γ secretion in response to whole insulin and antigens for CD8+ and CD4+ T cells. [ Time Frame: 78 Weeks ]
7. Luminex/Mesoscale assessment of serum cytokines IL-17, IFN-γ, IL-12p40, IL-12p70 and IL-23. [ Time Frame: 78 Weeks ]
8. Regulatory T cell (CD4+ FOXP3+): Effector T cell (CD4+ FOXP3-CD25+) ratio. [ Time Frame: 78 Weeks ]
9. CD154 and CD134 (OX40) based assays to determine diabetogenic antigen specific responses of T helper cells. [ Time Frame: 52 Weeks ]
10. Nanostring assessment of whole blood and PBMC RNA gene expression of IL-17 and IFN-γ family genes. [ Time Frame: 78 Weeks ]
11. Epigenetic assessment of Treg phenotype and function. [ Time Frame: 78 Weeks ]
12. Sequencing and profiling of microbiome. [ Time Frame: 78 Weeks ]
13. Glycaemic variability in continuous glucose monitoring and hypoglycaemia rates. [ Time Frame: 78 Weeks ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 25 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. A diagnosis of type 1 diabetes mellitus in accordance with the ADA/CDA criteria.
2. An interval of ≤100 days between the diagnosis and the first dose of the study drug.
3. Ability to provide documented informed consent.
4. Male or female, aged 18-25 years inclusive, at the time of the anticipated first dose of the study drug.
5. Evidence of residual functioning β cells. This will be assessed by a C-peptide level over 0.2nmol/L in the MMTT test.
6. Positive for at least one diabetes-related autoantibody.
7. Willing to record all insulin taken and blood glucose levels that are required for monitoring during the study, including reporting any hypoglycaemic events.

Exclusion Criteria:

1. No condition that, in the investigators' judgment, is likely to cause the subject to not be able to understand information in order to provide informed consent.
2. History of malignancy.
3. No significant and/or active disease in any body system that is likely to increase the risk to the subject or interfere with the subject's participation in the study.
4. No significant systemic infection during the 6 weeks before the first dose of the study drug.
5. No history of current or past active tuberculosis infection and no latent tuberculosis as per CDC guidelines.
6. Have used any other investigational drug within the 3 months prior to the first dose and/or intend on using any investigational drug for the duration of the study.
7. Prior or current treatment that is known to cause a significant, ongoing change in the course of T1D or immunological status.
8. Current or prior (within 30 days prior to first study drug dose) use of medications known to influence glucose tolerance.
9. No significant abnormal laboratory values during the screening period, other than those due to T1D.
10. Not pregnant, breastfeeding or planning to become pregnant during the 60 days after the last dose of the study drug.
11. Have not received any live vaccines within 30 days prior to the first study drug dose and are not expected to need to receive a vaccine during the study.
12. No prior allergic reaction, including anaphylaxis, to any component of the study drug product.
13. No prior allergic reaction, including anaphylaxis, to any human, humanized, chimeric or rodent antibody treatment.
14. Have not undergone any major surgery within the 30 day period prior to the first drug dose and not anticipating requiring surgery during the study period.
15. Negative results for Hepatitis B surface antigen and for antibodies to Hepatitis B core antigen, or evidence of Hepatitis B surface antibody > 10 IU, and negative for Hepatitis C. Negative results for HIV and not considered by the investigator to be at high risk for HIV infection.

Contacts and Locations

Contacts

Contact: Tom Elliott, MBBS, FRCPC; 604-683-3734 ext 1001; telliott@bcdiabetes.ca

Contact: Marla Inducil, Pharm, MD, CCRP; 604 628 7253 ext 7011; minducil@bcdiabetes.ca

Locations

Canada, British Columbia

BCDiabetes; Recruiting

Vancouver, British Columbia, Canada, V5Y 3W2

Contact: Marla Inducil, Pharm, MD, CCRP 604 628 7253 ext 7011 minducil@bcdiabetes.ca

Principal Investigator: Tom Elliott, MBBS, FRCPC

Sponsors and Collaborators

University of British Columbia

Juvenile Diabetes Research Foundation

Janssen, LP

Investigators

• Principal Investigator: Jan Dutz, MD FRCPC; University of British Columbia
• Study Director: Samuel Chow, MSc; University of British Columbia

More Information

• Responsible Party: Jan Dutz, Principal Investigator, University of British Columbia
• ClinicalTrials.gov Identifier: NCT03941132
• Other Study ID Numbers: H19-00411
• First Posted: May 7, 2019
• Last Update Posted: January 29, 2021
• Last Verified: January 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jan Dutz, University of British Columbia:

T1D; Ustekinumab; new-onset; diabetes

Additional relevant MeSH terms:

Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Ustekinumab; Dermatologic Agents